FLT3 and acute myeloid leukemia: Given that the measurement of FLT3-ITD mutations seemed to have a higher sensitivity when analyzing cDNA samples, we decided to evaluate whether it could be used as an MRD marker for monitoring patients with R/R FLT3-mutated AML treated with FLT3i.